Is Transgene S.A. (0OCQ.L) a Buy, Sell, or Hold?
LSE : 0OCQ.L
Transgene S.A.
$0.721 EUR
-$0.01 (-1.77%)
- Volume
- 282
- Average Volume
- 520
- Market Capitalization
- $103.97M
- P/E Ratio
- -2.78
- Dividend Yield
- 0.00%
- Price Target
- Year High
- $2.30
- Year Low
- $0.72
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $9.62
Company Overview
LSE
Alessandro Riva
Biotechnology
Healthcare
0OCQ.L
144
FR
EUR
Liquidity Metrics
0.02
9.62
9.62
0.54
0.00
Sales & Valuation
$137K
762.05
0.95
-2.78
-0.24
Profitability
-$0.26
-$37.52M
-27389.78%
-32294.89%
-63.53%
-27.03%
P/E Metrics
-2.78
-0.26
-0.26
Analyst Price Target & Rating
2/5
0 Analysts
%
Financial Health Scores
2.06
4/9
$105.45M
$138.83M
$17.09M
-$76.75M
Key Metrics (TTM)
No key metrics data available.
Company Executives
| Name | Title |
|---|---|
| Feriel Marin | Interim Chief Quality Officer |
| James Wentworth | Vice President & Chief Business Officer |
| John Felitti | Vice President, General Counsel & Corporate Secretary |
| Emmanuelle Dochy | Vice President of Medical Affairs & Chief Medical Officer |
| Lucie Larguier | Vice President & Chief Financial Officer |
| Christelle Schwoerer | Chief Human Resources Officer |
| Alessandro Riva | Chief Executive Officer & Chairman of the Board |
| Maurizio Ceppi | Chief Scientific Officer |
| Simone Silva Steiner | Chief Technical Officer |
| Katell Bidet Huang | Head of Translational Medicine |
Poll Results
No votes yet today — be the first to share your view!
About Transgene S.A. (LSE:0OCQ.L) Stock
Transgene SA is a biotechnology company focused on the research and development of therapeutic vaccines and oncolytic viruses, with a primary objective to treat cancer and infectious diseases. Its product pipeline includes TG4050, a therapeutic vaccine currently in Phase I clinical trials for ovarian cancer and head and neck cancers that are HPV-negative. Another therapeutic vaccine, TG4001, is undergoing Phase II clinical development for HPV-positive cancers. The company is also advancing oncolytic viruses such as TG6002, which is in Phase I/IIa trials for a variety of solid tumors, including gastrointestinal adenocarcinomas of the stomach, pancreas, and colon, and BT-001, an oncolytic virus in Phase I/II clinical trials for solid tumors. Additionally, Transgene is developing TG1050, a th ... erapeutic vaccine for chronic hepatitis B, and Pexa-Vec, an oncolytic virus intended for solid tumor treatment. The company has established numerous strategic collaborations and licensing agreements with key industry players, including AstraZeneca, Merck KGaA, Pfizer, PersonGen BioTherapeutics, NEC Corporation, SillaJen, Ascend BioPharmaceutical, Valneva, Sanofi, BioInvent, and Randox. Founded in 1979, Transgene SA is headquartered in Illkirch-Graffenstaden, France, and operates as a subsidiary of TSGH SAS.
Frequently Asked Questions
-
What is the current Transgene S.A. (0OCQ.L) stock price?
-
Transgene S.A.(LSE:0OCQ.L) stock price is $0.721 in the last trading session. During the trading session, 0OCQ.L stock reached the peak price of $2.295 while $0.721 was the lowest point it dropped to. The percentage change in 0OCQ.L stock occurred in the recent session was --1.77% while the dollar amount for the price change in 0OCQ.L stock was -$0.01.
-
0OCQ.L's industry and sector of operation?
-
The LSE listed 0OCQ.L is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of 0OCQ.L?
-
Feriel Marin | Interim Chief Quality Officer
James Wentworth | Vice President & Chief Business Officer
John Felitti | Vice President, General Counsel & Corporate Secretary
Emmanuelle Dochy | Vice President of Medical Affairs & Chief Medical Officer
Lucie Larguier | Vice President & Chief Financial Officer -
How many employees does 0OCQ.L have?
-
Number of 0OCQ.L employees currently stands at 144. 0OCQ.L operates from 400, Boulevard Gonthier d’Andernach, Illkirch-Graffenstaden, GE 67405, FR.
-
Link for 0OCQ.L official website?
-
Official Website of 0OCQ.L is: https://www.transgene.fr
-
How do I contact 0OCQ.L?
-
0OCQ.L could be contacted at phone #33 3 88 27 91 00 and can also be accessed through its website. 0OCQ.L operates from 400, Boulevard Gonthier d’Andernach, Illkirch-Graffenstaden, GE 67405, FR.
-
How many shares of 0OCQ.L are traded daily?
-
The average number of 0OCQ.L shares traded daily for last 3 months was 520.
-
What is the market cap of 0OCQ.L currently?
-
The market value of 0OCQ.L currently stands at $103.97M with its latest stock price at $0.721